Core Viewpoint - The report outlines Zhejiang Jiuzhou Pharmaceutical Co., Ltd.'s commitment to enhancing quality and efficiency while returning value to shareholders through strategic initiatives and financial performance [1][2]. Group 1: Focus on Core Business and High-Quality Development - The company is an industry-leading CDMO enterprise, emphasizing innovation and customer service to support global drug development [1]. - In the first half of the year, the company achieved operating revenue of 2.871 billion yuan and a net profit attributable to shareholders of 526 million yuan [1]. - The company received multiple accolades, including being ranked among the top 20 Chinese pharmaceutical CDMO companies and receiving a "Gold Medal" certification from EcoVadis for corporate social responsibility [1]. Group 2: Continuous Cash Dividends and Shareholder Returns - The company prioritizes shareholder interests by consistently implementing cash dividends, distributing over 30% of the annual net profit since its listing in 2014 [2]. - For the 2024 annual profit distribution, the company plans to distribute 3.00 yuan per 10 shares, totaling approximately 265.76 million yuan, which represents 60.33% of the 2024 net profit [2]. - The mid-year profit distribution plan for 2025 proposes a dividend of 2.00 yuan per 10 shares, amounting to 52.93% of the mid-year net profit [2]. Group 3: Share Buyback Plans - The company intends to use between 100 million yuan and 200 million yuan for a share buyback program to enhance investor confidence and promote long-term stability [3]. - As of May 15, 2025, the company completed a buyback of 7,736,000 shares for a total payment of approximately 101.99 million yuan [3]. Group 4: Accelerating New Productive Forces - The company focuses on R&D innovation as a core driver of growth, leveraging its extensive experience in drug development and proprietary green pharmaceutical technologies [4][5]. - Collaborations with academic institutions have led to significant advancements in chemical synthesis and continuous reaction technologies [5]. Group 5: Enhancing Communication Channels and Company Value - The company aims to optimize information disclosure and improve investor relations by providing clear and accessible reports [6]. - Active participation in investor engagement activities, such as shareholder meetings and performance briefings, fosters trust and collaboration with investors [6]. Group 6: Strengthening Governance Mechanisms - The company adheres to legal regulations and continuously improves its governance practices to ensure effective operation [7]. - The company has received recognition for its ESG efforts, including being included in the FTSE Russell Social Responsibility Index and achieving a "Gold Medal" rating from EcoVadis [7].